Dhrita Khatri

Dhrita Khatri

Auto-generated profile, based on publicly available information

Dhrita Khatri

Cancer Therapies Group Murdoch Children's Research Institute Parkville Australia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
AHAndreas Halman
Andreas Halman
RCRachel Conyers
Rachel Conyers
CMClaire Moore
Claire Moore
DKDhrita Khatri
Dhrita Khatri
JSJerome Sarris
Jerome Sarris
DPDaniel Perkins
Daniel Perkins
Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these topics to explore the utility of pharmacogenomics (a key component of personalized medicine) in psychedelic‐assisted therapies. We summarized the literature and explored the potential implications of genetic variability on the pharmacodynamics and pharmacokinetics of psychedelic drugs including lysergic acid diethylamide (LSD), psilocybin, N,N‐dimethyltryptamine (DMT), 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT), ibogaine and 3,4‐methylenedioxymethamphetamine (MDMA). Although existing evidence is limited, particularly concerning pharmacodynamics, studies investigating pharmacokinetics indicate that genetic variants in drug‐metabolizing enzymes, such as cytochrome P450, impact the intensity of acute psychedelic effects for LSD and ibogaine, and that a dose reduction for CYP2D6 poor metabolizers may be appropriate. Furthermore, based on the preclinical evidence, it can be hypothesized that CYP2D6 metabolizer status might contribute to altered acute psychedelic experiences with 5‐MeO‐DMT and psilocybin when combined with monoamine oxidase inhibitors. In conclusion, considering early evidence that genetic factors can influence the effects of certain psychedelics, we suggest that pharmacogenomic testing should be further investigated in clinical research. This is necessary to evaluate its utility in improving the safety and therapeutic profile of psychedelic therapies and a potential future role in personalizing psychedelic‐assisted therapies, should these treatments become available.

10 May 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
CMClaire Moore
Claire Moore
AHAndreas Halman
Andreas Halman
TSTayla Stenta
Tayla Stenta
DKDhrita Khatri
Dhrita Khatri
EWElizabeth Williams
Elizabeth Williams
RCRachel Conyers
Rachel Conyers
Pharmacogenomics remains underutilized in pediatric oncology, despite the existence of evidence‐based guidelines. Implementation of pharmacogenomics‐informed prescribing could improve medication safety and efficacy in pediatric oncology patients, who are at high risk of adverse drug reactions. This study examines the prevalence of high‐risk pharmacogenomic phenotypes and the prescription of relevant medications in a diverse Australian pediatric oncology cohort, highlighting the potential impact of pharmacogenomic testing in this unique population. Whole genome sequencing data from 180 patients were analyzed to assess 14 genes with evidence‐based pharmacogenomic guidelines relevant to pediatric oncology. Over 90% of patients had at least one high‐risk phenotype, with 20% presenting four or more. Ondansetron, mercaptopurine, omeprazole, pantoprazole, and voriconazole were commonly prescribed medications that have pharmacogenomic prescribing recommendations, with the latter three showing the highest actionability rates. High‐risk phenotypes were most frequently observed for CYP2C19 and CYP2D6, with 30% of patients having a high‐risk phenotype for both genes. This study underscores the potential utility of pharmacogenomics in pediatric oncology patients across a range of pharmacogenes and commonly prescribed medications. The findings support advocacy for implementing broad, pre‐emptive pharmacogenomic testing in oncology patients to improve treatment safety and efficacy.

3 February 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
CMClaire Moore
Claire Moore
EWElizabeth Williams
Elizabeth Williams
RDRoxanne Dyas
Roxanne Dyas
AHAndreas Halman
Andreas Halman
TSTayla Stenta
Tayla Stenta
RCRachel Conyers
Rachel Conyers
5‐hydroxytryptamine‐3 (5‐HT3) receptor antagonists including ondansetron, tropisetron, dolasetron, palonosetron, granisetron, and ramosetron are commonly used to prevent and treat nausea and vomiting. Most of these medications are at least partially metabolized via the highly polymorphic CYP2D6 enzyme, resulting in variations of metabolism among individuals. Current (2017) international prescribing guidelines for ondansetron/tropisetron use according to genotype provide recommendations for CYP2D6 ultrarapid metabolizers but not intermediate or poor metabolizers. However, multiple studies have been conducted since this guideline was published. This review evaluated all available evidence of an association between CYP2D6 genotype and 5‐HT3 receptor antagonist outcomes, including in patients who are CYP2D6 intermediate/poor metabolizers and pediatric‐specific studies. In this review, we confirm that CYP2D6 genotype impacts ondansetron response in a postoperative nausea and vomiting setting, which was supported by a meta‐analysis. We also highlight the heterogeneity and limitations of included studies as well as provide future directions for pharmacogenomics research.

15 August 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
DKDhrita Khatri
Dhrita Khatri
BFBen Felmingham
Ben Felmingham
CMClaire Moore
Claire Moore
SLSmaro Lazaraki
Smaro Lazaraki
TSTayla Stenta
Tayla Stenta
RCRachel Conyers
Rachel Conyers
Tacrolimus, a calcineurin inhibitor, is a highly effective immunosuppressant used in solid organ transplantation (SOT). However, it is characterized by a narrow therapeutic range and high inter‐patient variability in pharmacokinetics. Standard weight‐based dosing followed by empiric dose titration is suboptimal in controlling drug concentrations, increasing risk of rejection or toxicity, particularly in the initial months post transplantation. This review explores the potential of combined pre‐transplant genotyping and pharmacokinetic (PK) modelling to improve tacrolimus dosing in paediatric SOT recipients. A systematic search of Medline, Embase and Cochrane databases identified studies published between March 2013 and March 2023 that investigated genotype‐ and PK model‐informed tacrolimus dosing in children post‐SOT. The Newcastle‐Ottawa Scale assessed study quality. Seven studies encompassing paediatric kidney, heart, liver and lung transplants reported using genotype and model‐informed dosing. A combination of clinical and genetic factors significantly impacts tacrolimus clearance and thus initial dose recommendation. Body size, transplant organ and co‐medications were consistently important, while either time post‐transplant or haematocrit emerged in some studies. Several models were identified, however, with limitations evident in some and with absence of evidence for their effectiveness in optimizing initial and subsequent dosing. This review highlights the development of PK models in paediatric SOT that integrate genotype and clinical covariates to personalize early tacrolimus dosing. While promising, prospective studies are needed to validate and confirm their effectiveness in improving time to therapeutic concentrations and reducing under‐ or overexposure. This approach has the potential to optimize tacrolimus therapy in paediatric SOT, thereby improving outcomes.

21 April 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
RCRachel Conyers
Rachel Conyers
TSTayla Stenta
Tayla Stenta
ASAndrew A. Somogyi
Andrew A. Somogyi
CKCarl Michael James Kirkpatrick
Carl Michael James Kirkpatrick
AHAndreas Halman
Andreas Halman
MAMarliese Alexander
Marliese Alexander
Phenoconversion is the discrepancy between genotype‐predicted phenotype and clinical phenotype, due to nongenetic factors. In oncology patients, the impact of phenoconversion on drug selection, efficacy, toxicity, and treatment outcomes is unknown. This study will assess acceptability and feasibility of investigating phenoconversion using probe medications in a pediatric and adolescent and young adult (AYA) oncology population. This prospective, single‐arm, single‐blind, nonrandomized feasibility study, will enroll individuals aged 6–25 years with a new diagnosis of Hodgkin Lymphoma or Non‐Hodgkin Lymphoma. Genotyping will be performed at baseline using whole genome sequencing or targeted panel testing. Longitudinal phenotyping will be conducted throughout the cancer treatment using exogenous oral enzyme‐specific probes, specifically subtherapeutic dextromethorphan (CYP2D6) and omeprazole (CYP2C19, CYP3A4) for enzyme activity assessment. The primary outcome measure will be the proportion of patients who consent to the study and successfully complete baseline and at least two longitudinal time points with valid probe drug metabolic ratio measurements. Secondary outcomes include classification of clinical phenotypes based on probe drug metabolic ratios, probe drug safety, barriers to consent, acceptability of pharmacogenomic and phenoconversion testing, longitudinal genotype/phenotype concordance, inflammatory profiles, and patient and disease factors influencing phenoconversion. The trial has received ethics approval (2023/ETH1954) and is registered at ClinicalTrials.gov (NCT06383338). Findings will be disseminated through peer‐reviewed publications and professional conferences, providing critical insights to advance the understanding of phenoconversion in oncology from pediatrics to adults. These results will help shape future research and drive the implementation of more personalized precision medicine strategies for all people with cancer.

4 September 2025 in Genetics in Medicine Open
Verified
Journal Article
Open access
CMClaire Moore
Claire Moore
EMEmma F Magavern
Emma F Magavern
MAMarliese Alexander
Marliese Alexander
SHSafeera Hussainy
Safeera Hussainy
TDTracey Danaher
Tracey Danaher
RCRachel Conyers
Rachel Conyers
Preemptive pharmacogenomic (PGx) testing in pediatric oncology patients could reduce toxicity and improve efficacy of medications yet remains underutilized. Consumer identified implementation barriers have not been extensively explored nor included adolescent or young adult (AYA) patient perspectives. This study describes Australian pediatric oncology consumer perspectives on PGx testing, elucidating barriers to implementation. A theory-informed, quantitative survey was used to assess knowledge and attitudes toward PGx in 38 AYA patients and 66 caregivers. Additionally, AYAs were assessed for autonomy using a validated scale. Participants viewed PGx testing positively, and 98% at least “somewhat agreed” that they would want to be tested/want their child to be tested. Concerns were identified in both AYA patient and caregiver groups, primarily the possibility of insurance discrimination and data security. Almost 90% of AYA patients expressed a desire for direct involvement in decisions regarding their PGx testing. However, the mean autonomy score (15.2) suggests that many felt they were not consistently given the opportunity to participate in decisions about their own lives. Despite positive attitudes toward PGx testing, pediatric oncology consumers still have some concerns that need to be addressed for successful implementation. Additionally, AYA patients should be included in PGx processes and implementation design.